Antengene has plans to assess an Exportin 1 (XPO1) inhibitor, selinexor, in a Phase II clinical trial for the treatment of myelofibrosis (MF) patients in China.

China’s National Medical Products Administration (NMPA) has accepted the company’s investigational new drug (IND) application to conduct the trial.

Karyopharm Therapeutics discovered and developed selinexor, which is an oral selective inhibitor of nuclear export (SINE) compound and marketed as Xpovio in the US.

Under an exclusive development and marketing deal for some Asia-Pacific markets and the ASEAN countries, Antengene is presently developing the SINE compound.

The randomised, open-label, multi-centre Phase II trial will compare the safety and efficacy of selinexor to physician’s choice (PC) in MF subjects who received a minimum of six months of treatment with a Janus kinase 1/2 inhibitor.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will enrol a total of about 112 subjects at 75 trial sites globally. Participants will be categorised in a 1:1 ratio to receive either selinexor or PC treatment.

Antengene founder, chairman and CEO Dr Jay Mei said: “This acceptance by the NMPA of the IND application for the China study of selinexor in patients with MF marks another major step forward in our effort to develop selinexor into a novel cancer drug.

“It also paves the way for our ongoing exploration of additional indications for Antengene’s novel assets.”

MF is a clonal hematologic neoplasm that can occur as primary MF, polycythemia vera or essential thrombocythemia.

Currently, the company is carrying out five late-stage trials of selinexor to treat multiple myeloma, diffuse large B-cell lymphoma, non-small cell lung cancer and peripheral T and NK/T-cell lymphoma.

The SINE compound received priority review designation from the NMPA, as well as orphan drug status from the Ministry of Food and Drug Safety of South Korea.

Earlier this year, selinexor (Nexpovio) obtained conditional marketing authorisation from the European Commission to treat relapsed/refractory multiple myeloma in adults.

Antengene dosed the first subject in a Phase I/II HATCH trial of eltanexor (ATG-016) for treating patients with intermediate and higher-risk myelodysplastic syndrome in China in May 2021.